The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out a key provision that would have expanded coverage for weight-loss drugs. In response, Eli Lilly stock ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...